File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: c-mos Immunoreactivity Aids in the Diagnosis of Gestational Trophoblastic Lesions

Titlec-mos Immunoreactivity Aids in the Diagnosis of Gestational Trophoblastic Lesions
Authors
KeywordsC-mos
Choriocarcinoma
Germ cell tumor
Gestational trophoblastic disease
Gynecological neoplasm
Hydatidiform mole
Issue Date2004
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.intjgynpathology.com
Citation
International Journal Of Gynecological Pathology, 2004, v. 23 n. 2, p. 145-150 How to Cite?
AbstractC-mos is an important proto-oncogene involved in the mitogen-activating protein kinase pathway. This study was designed to explore c-mos immunoreactivity in gestational trophoblastic lesions and compare it with immunoreactivity in normal placentas as well as other gynecological lesions and germ cell tumors using antibody P-19. The immunohistochemical distribution of c-mos in 159 cases of gynecological lesions and 26 germ cell tumors using formalin-fixed, paraffin-embedded tissues was evaluated. The lesions included 45 (32 complete and 13 partial) hydatidiform moles, 17 choriocarcinomas, 5 placental site trophoblastic tumors, 18 squamous cell carcinomas and 5 adenocarcinomas of the cervix, 11 endometrial carcinomas, 9 ovarian carcinomas, 4 primary peritoneal papillary serous carcinomas, 9 low-grade endometrial stromal sarcomas, 4 epithelioid leiomyomas, 6 leiomyosarcomas, and 26 gem cell tumors (3 embryonal carcinomas, 5 yolk sac tumors, 6 immature teratomas, and 3 mature teratomas from the ovary; 9 testicular seminomas). Twenty-six normal placentas also were included for comparison. Among cases of gestational trophoblastic diseases, c-mos immunoreactivity was found in all hydatidiform moles and choriocarcinomas, but in none of the placental site trophoblastic tumors. The c-mos staining pattern was similar in trophoblastic diseases and normal placentas with strong expression in syncytiotrophoblast, moderate expression in villous intermediate trophoblast, and predominantly negative expression in implantation site intermediate trophoblast, chorionic-type intermediate trophoblast, and villous cytotrophoblast. All the nontrophoblastic tumors, including carcinomas, sarcomas, and germ cell tumors, were negative for c-mos expression. Immunohistochemical detection of c-mos is useful in differentiating choriocarcinoma from placental site trophoblastic tumor and nontrophoblastic tumors of the female genital tract that may sometimes cause problems in differential diagnosis.
Persistent Identifierhttp://hdl.handle.net/10722/67786
ISSN
2022 Impact Factor: 2.4
2020 SCImago Journal Rankings: 0.925
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorXue, WCen_HK
dc.contributor.authorKhoo, USen_HK
dc.contributor.authorNgan, HYSen_HK
dc.contributor.authorChan, KYKen_HK
dc.contributor.authorIp, PPCen_HK
dc.contributor.authorTsao, SWen_HK
dc.contributor.authorCheung, ANYen_HK
dc.date.accessioned2010-09-06T05:58:14Z-
dc.date.available2010-09-06T05:58:14Z-
dc.date.issued2004en_HK
dc.identifier.citationInternational Journal Of Gynecological Pathology, 2004, v. 23 n. 2, p. 145-150en_HK
dc.identifier.issn0277-1691en_HK
dc.identifier.urihttp://hdl.handle.net/10722/67786-
dc.description.abstractC-mos is an important proto-oncogene involved in the mitogen-activating protein kinase pathway. This study was designed to explore c-mos immunoreactivity in gestational trophoblastic lesions and compare it with immunoreactivity in normal placentas as well as other gynecological lesions and germ cell tumors using antibody P-19. The immunohistochemical distribution of c-mos in 159 cases of gynecological lesions and 26 germ cell tumors using formalin-fixed, paraffin-embedded tissues was evaluated. The lesions included 45 (32 complete and 13 partial) hydatidiform moles, 17 choriocarcinomas, 5 placental site trophoblastic tumors, 18 squamous cell carcinomas and 5 adenocarcinomas of the cervix, 11 endometrial carcinomas, 9 ovarian carcinomas, 4 primary peritoneal papillary serous carcinomas, 9 low-grade endometrial stromal sarcomas, 4 epithelioid leiomyomas, 6 leiomyosarcomas, and 26 gem cell tumors (3 embryonal carcinomas, 5 yolk sac tumors, 6 immature teratomas, and 3 mature teratomas from the ovary; 9 testicular seminomas). Twenty-six normal placentas also were included for comparison. Among cases of gestational trophoblastic diseases, c-mos immunoreactivity was found in all hydatidiform moles and choriocarcinomas, but in none of the placental site trophoblastic tumors. The c-mos staining pattern was similar in trophoblastic diseases and normal placentas with strong expression in syncytiotrophoblast, moderate expression in villous intermediate trophoblast, and predominantly negative expression in implantation site intermediate trophoblast, chorionic-type intermediate trophoblast, and villous cytotrophoblast. All the nontrophoblastic tumors, including carcinomas, sarcomas, and germ cell tumors, were negative for c-mos expression. Immunohistochemical detection of c-mos is useful in differentiating choriocarcinoma from placental site trophoblastic tumor and nontrophoblastic tumors of the female genital tract that may sometimes cause problems in differential diagnosis.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.intjgynpathology.comen_HK
dc.relation.ispartofInternational Journal of Gynecological Pathologyen_HK
dc.rightsInternational Journal of Gynecological Pathology. Copyright © Lippincott Williams & Wilkins.en_HK
dc.subjectC-mosen_HK
dc.subjectChoriocarcinomaen_HK
dc.subjectGerm cell tumoren_HK
dc.subjectGestational trophoblastic diseaseen_HK
dc.subjectGynecological neoplasmen_HK
dc.subjectHydatidiform moleen_HK
dc.subject.meshDiagnosis, Differentialen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGenital Neoplasms, Female - metabolism - pathologyen_HK
dc.subject.meshGestational Trophoblastic Disease - metabolism - pathologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunohistochemistryen_HK
dc.subject.meshPlacenta - metabolismen_HK
dc.subject.meshPregnancyen_HK
dc.subject.meshProto-Oncogene Proteins c-mos - biosynthesisen_HK
dc.subject.meshTumor Markers, Biological - analysisen_HK
dc.titlec-mos Immunoreactivity Aids in the Diagnosis of Gestational Trophoblastic Lesionsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0277-1691&volume=23&issue=2&spage=145&epage=150&date=2004&atitle=c-mos+immunoreactivity+aids+in+the+diagnosis+of+gestational+trophoblastic+lesionsen_HK
dc.identifier.emailKhoo, US: uskhoo@hku.hken_HK
dc.identifier.emailNgan, HYS: hysngan@hkucc.hku.hken_HK
dc.identifier.emailChan, KYK: kelvinc@pathology.hku.hken_HK
dc.identifier.emailTsao, SW: gswtsao@hku.hken_HK
dc.identifier.emailCheung, ANY: anycheun@hkucc.hku.hken_HK
dc.identifier.authorityKhoo, US=rp00362en_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.identifier.authorityChan, KYK=rp00453en_HK
dc.identifier.authorityTsao, SW=rp00399en_HK
dc.identifier.authorityCheung, ANY=rp00542en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/00004347-200404000-00009en_HK
dc.identifier.pmid15084843-
dc.identifier.scopuseid_2-s2.0-1642271865en_HK
dc.identifier.hkuros86776en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-1642271865&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume23en_HK
dc.identifier.issue2en_HK
dc.identifier.spage145en_HK
dc.identifier.epage150en_HK
dc.identifier.isiWOS:000220452800009-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridXue, WC=7103165268en_HK
dc.identifier.scopusauthoridKhoo, US=7004195799en_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK
dc.identifier.scopusauthoridChan, KYK=7406034195en_HK
dc.identifier.scopusauthoridIp, PPC=7003622683en_HK
dc.identifier.scopusauthoridTsao, SW=7102813116en_HK
dc.identifier.scopusauthoridCheung, ANY=54927484100en_HK
dc.identifier.issnl0277-1691-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats